Skip to main content
UNHUnitedHealth Group IncorporatedHold5.6·$420.12-0.81%
HoldModerate Confidence
Investment thesis

UnitedHealth Group trades at a quality score of only 4.1 out of 10 with no identified competitive moat, is trading at or above analyst target resistance with negative asymmetry, and has an active legal news gate failure — three simultaneous risk factors that collectively prevent a favorable entry at current prices.

Thesis pillars

  • Quality Below Average No MoatStable
  • Legal News Gate Active RiskStable
  • Below Analyst Target Negative AsymmetryImproving
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

UnitedHealth Group Incorporated (UNH) Stock Analysis

HoldGrowthModerate Confidence

Healthcare · Healthcare Plans

Hold if already holding. Not a fresh buy at $420.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: risk-based products (80.0%); Analyst target reached - limited upside remaining.

UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and UnitedHealthcare (health benefits for employers, individuals, Medicare, and Medicaid). Revenue is predominantly generated through risk-based health insurance... Read more

$420.12+1.7% A.UpsideScore 5.6/10#5 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield5.96%
IncomeYield2.19%(5y avg 1.65%)Payout66.57%
Stop $400.85Target $427.71(analyst − 10%)A.R:R 0.3:1
Analyst target$475.23+13.1%26 analysts
$427.71our TP
$420.12price
$475.23mean
$313
$529

Hold if already holding. Not a fresh buy at $420.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: risk-based products (80.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 94d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About UnitedHealth Group Incorporated

About UnitedHealth Group Incorporated

UnitedHealth Group's health benefit plans covered 29.7 million Employer & Individual members, 8.4 million Medicare Advantage enrollees, and nearly 7.4 million Medicaid members across 32 states and the District of Columbia as of December 31, 2025. CMS premium revenues represented 44% of total consolidated revenues in 2025, and risk-based premiums constituted nearly 80% of all revenues. Optum Rx managed $188 billion in pharmaceutical spending, including nearly $87 billion in specialty pharmaceuticals, through a network of approximately 64,000 retail pharmacies.

UnitedHealth Group earns revenue through two complementary mechanisms. UnitedHealthcare charges monthly premiums to cover medical and administrative costs across employer, individual, Medicare, and Medicaid markets: Medicare Advantage premiums are set by CMS based on geographic area, demographic factors, and health status, while Medicaid premiums are negotiated under state contracts. UnitedHealthcare Community & State operated in 32 states and the District of Columbia as of December 31, 2025, serving nearly 7.4 million people through CHIP, Dual SNPs, Long-Term Services and Supports, and Medicaid expansion in 19 states. Optum's three businesses — Optum Health (patient-centered care for 95 million consumers), Optum Insight (analytics and technology services with a $31.1 billion backlog as of December 31, 2025), and Optum Rx (pharmacy benefit management) — generate fee, performance, and spread-based revenue. Optum Insight's $31.1 billion backlog included $18.3 billion expected to be recognized within 12 months and $12.9 billion related to affiliated agreements.

Show full overview

CMS's 44% share of consolidated revenues exposes UnitedHealth Group to annual Medicare Advantage rate-setting decisions. CMS retains the right to audit medical loss ratios and risk adjustment data submissions, with premium payments varying based on geographic area, demographics, and enrollee health status — all set externally each year. The 10-K notes that relatively small differences between predicted and actual medical costs as a percentage of revenues have resulted and may in future periods result in significant financial impact, a sensitivity amplified by the nearly 80% share of revenues tied to risk-based arrangements where cost overruns cannot be recovered within the fixed premium year.

See also: Healthcare · Healthcare Plans

From UnitedHealth Group Incorporated's most recent 10-K filing, extracted June 16, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-26
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Oct 27, 202694d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (3/4)
Positive insider activity
Risks
Concentration risk — Product: risk-based products (80.0%)
Analyst target reached - limited upside remaining
Negative momentum

Key Metrics

P/E (TTM)31.6
P/E (Fwd)18.8
Mkt Cap$382.1B
EV/EBITDA17.5
Profit Mgn3.1%
ROE14.2%
Rev Growth0.4%
Beta0.63
Dividend2.19%
Rating analysts34

Quality Signals

Piotroski F7/9

Options Flow

P/C1.33bearish
IV40%normal

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerCMS44%
    10-K Item 1: 'Premium revenues from CMS represented 44% of UnitedHealth Group's total consolidated revenues for the year ended December 31, 2025'
  • HIGHProductrisk-based products80%
    10-K Item 1A: 'Premium revenues from risk-based products constitute nearly 80% of our total consolidated revenues'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.9
Obv
1.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.7<4.5A.R:R 0.3 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 94d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
52 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $413.25Resistance $461.62

Price Targets

$401
$428
A.Upside+1.7%
A.R:R0.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (1.7% upside)
! momentum at 2.7 (below the engine's 4.5 threshold)
! asymmetry at 0.3 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-10-27 (94d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is UNH stock a buy right now?

Hold if already holding. Not a fresh buy at $420.12, but acceptable to hold if already in. Reasons: Concentration risk — Product: risk-based products (80.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $427.71 (+1.8%), stop $400.85 (−4.8%), A.R:R 0.3:1. Score 5.6/10, moderate confidence.

What is the UNH stock price target?

Take-profit target: $427.71 (+1.7% upside). Target $427.71 (+1.8%), stop $400.85 (−4.8%), A.R:R 0.3:1. Stop-loss: $400.85.

What are the risks of investing in UNH?

Concentration risk — Product: risk-based products (80.0%); Analyst target reached - limited upside remaining; Negative momentum.

Is UNH overvalued or undervalued?

UnitedHealth Group Incorporated trades at a P/E of 31.6 (forward 18.8). TrendMatrix value score: 5.5/10. Verdict: Hold.

What do analysts say about UNH?

34 analysts cover UNH with a consensus score of 4.0/5. Average price target: $475.

What does UnitedHealth Group Incorporated do?UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and...

UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and UnitedHealthcare (health benefits for employers, individuals, Medicare, and Medicaid). Revenue is predominantly generated through risk-based health insurance premiums (nearly 80% of total revenues), with CMS premiums representing 44% of consolidated revenues in 2025 from Medicare Advantage's 8.4 million enrollees and Medicaid programs across 32 states.

Related stocks: CI (The Cigna Group) · CVS (CVS Health Corporation) · ELV (Elevance Health, Inc.) · HUM (Humana Inc.)
Home Stocks UNH

Latest news

Latest News

Barron's10d agoEarnings
Yahoo Finance11d ago
Benzinga11d agoEarnings
The Motley Fool17d ago
CNN5d ago
Investopedia12d agoEarnings
Schaeffer's Investment Research12d agoEarnings
Stocktwits18d agoProduct
Kavout | AI9d ago
Investor's Business Daily10d ago
The Motley Fool10d agoEarnings
Barron's10d ago
TradingKey10d ago
Reuters10d ago
Investing.com10d ago
Benzinga10d ago
Qz.com10d ago
Qz.com10d ago
Qz.com10d ago
StockStory10d ago
Loading more...